News

 
News

April 24, 2023Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures 

 
January 13,2023 
Please Join ABio-X CEO Jeff Jonas and various industry experts on Wednesday, January 18th, from 2 to 3 p.m. ET as we look at what’s to come for the biotech sector in 2023. Take a look at some of the questions we’ll be debating below: Will pharmaceutical companies take a more active role in dealmaking? 
What clinical trial readouts could shape R&D investments?
Will demand for IPOs bounce back?
ABio-X:Overview | LinkedIn

April 28, 2021Adcentrx Therapeutics Announces Completion of $50M Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development. 
Read more

April 6, 2022
ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic EnsembleTM platform and accelerate R&D pipeline.
Read more 

February 14, 2022 Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates 

November 10, 2022CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO

April 24, 2023

Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures

January 13,2023

Please Join ABio-X CEO Jeff Jonas and various industry experts on Wednesday, January 18th, from 2 to 3 p.m. ET as we look at what’s to come for the biotech sector in 2023. Take a look at some of the questions we’ll be debating below:

ABio-X:Overview | LinkedIn

April 28, 2021

April 6, 2022ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic EnsembleTM platform and accelerate R&D pipeline.Read more

February 14, 2022

Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates

November 10, 2022

CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO

April 6, 2022
ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic Ensemble^TM platform and accelerate R&D pipeline.
Read more